Peer-reviewed veterinary case report
Immunohistochemical markers that predict skin mast cell tumors in dogs
By Freytag, Jennifer Ostrand et al.·Published in Veterinary and comparative oncology·2021·Department of Pathology, Brazil·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Prognostic value of immunohistochemical markers in canine cutaneous mast cell tumours: A systematic review and meta-analysis.
- Species:
- dog
Plain-English summary
A study found that dogs with skin tumors called mast cell tumors (MCTs) can have different outcomes based on certain markers found in the tumor tissue. Specifically, higher levels of markers Ki-67 and BAX, as well as abnormal levels of KIT, were linked to a greater chance of death. This means that if your dog has a mast cell tumor, these markers could help your vet predict how serious the situation might be. However, the study also noted that not all research provides enough information to fully understand these markers' effects.
People also search for: dog mast cell tumor prognosis · Ki-67 in dog tumors · treatment for canine mast cell tumors
Abstract
Histological grading systems remain cornerstones in the prognosis of canine cutaneous mast cell tumours (MCTs), but the distinct biological behaviour of each tumour often necessitates the use of complementary markers. Although a plethora of immunohistochemical markers have been proposed as prognostic factors, few are presently applied in routine diagnosis. This systematic review and meta-analysis was designed to establish which immunohistochemical markers have verifiable prognostic value for cutaneous MCTs in dogs. A Boolean search of five databases identified 200 articles for screening, of which 73 were selected for full-text assessment and 24 ultimately included in the systematic review. Odds Ratio (OR) was adopted as the summary measure for subsequent meta-analysis but only 15 articles, relating to the immunomarkers Ki-67 (9), KIT (5), and BAX (2), provided either a value for OR or sufficient data to calculate this statistic. Meta-analysis verified that canine cutaneous MCTs with elevated expression of Ki-67 or BAX, as well aberrant immuno-expression of KIT, showed an increased odds of death, with respective OR values of 11.2 (95% CI 6.3-20.0; p < .01), 9.9 (95% CI 1.3-73.6; p = .03), and 4.1 (95% CI 1.1-15.3; p = .03). Despite KIT, Ki67, and BAX arise as suitable prognostic factor for canine MCTs, this study highlighted the lack of important clinical and statistical data in many published articles, rendering it impossible to complete the meta-analysis of several potentially valuable immunohistochemical markers.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/33724647/